Drug
Nafamostat clinical trials
- studies test it
- 22
- open now
- 9
- in phase 3
- 5
- first study started
- 2007
Keep track of what changes. Save the nafamostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
22 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2020 | 7 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 5
- Phase 4
- 6
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 16
Ensysce Biosciences (3) · Chong Kun Dang Pharmaceutical (3) · University of Melbourne (1) · University of Edinburgh (1) · Kyungpook National University Hospital (1) · Yonsei University (1) · Seoul National University Hospital (1) · Jianfeng Xie (1)
Often tested with
Tested in the same studies.
PF614 (2) · Enoxaparin (1) · Dalteparin (1) · Tinzaparin (1) · Nirmatrelvir (1) · Ritonavir (1) · Remdesivir (1) · GB-0139 (1)
Studies
Open first, then newest update. How each study uses nafamostat is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic AnticoagulationRecruitingNot applicableBeijing Chao Yang HospitalNCT06676085Written as Nafamostat
- Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney InjuryNot yet recruitingPhase 4Jianfeng XieNCT07518303Written as Nafamostat Mesylate
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)RecruitingPhase 1Ensysce BiosciencesNCT06500793Written as Nafamostat Mesylate
- Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMORecruitingNot applicableXiaotong HouNCT06276010Written as nafamostat mesilate
- The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing HemofiltrationNot yet recruitingNot applicableThe First Hospital of Jilin UniversityNCT06994312Written as Nafamostat Mesylate
- The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot StudyRecruitingNot applicableWonju Severance Christian HospitalNCT05874674Written as Nafamostat Mesylate
- Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKINot yet recruitingPhase 4Shen LeiNCT06375616Written as Nafamostat Mesylate
- Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)RecruitingPhase 2/3University Hospital PadovaNCT04352400Written as Nafamostat Mesilate
- Nafamostat Mesilate in the Treatment of Severe Infection-associated CoagulopathyNot yet recruitingPhase 4Xu LiNCT06078839Written as Nafamostat mesilate
- DEFINE - Evaluating Therapies for COVID-19CompletedPhase 1/2University of EdinburghNCT04473053Written as Nafamostat Mesilate
- Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)CompletedPhase 1Ensysce BiosciencesNCT05090280Written as Nafamostat Mesylate
- Oral Nafamostat in Healthy Volunteers (NAF-101)CompletedPhase 1Ensysce BiosciencesNCT04406415Written as Nafamostat Mesilate
- Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in SenegalTerminatedPhase 3Institut Pasteur de DakarNCT04390594Written as Nafamostat Mesilate
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingPhase 3University of MelbourneNCT04483960Written as (Arm Closed) Nafamostat Mesilate
- Efficacy and Safety of Nafamostat Mesylate for VV-ECMO AnticoagulationStatus unknownPhase 2Xiaobo Yang, MDNCT05555641Written as Nafamostat Mesylate
- A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 PneumoniaCompletedPhase 2Chong Kun Dang PharmaceuticalNCT04628143Written as Nafamostat Mesilate
- Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314Status unknownPhase 3Chong Kun Dang PharmaceuticalNCT04871646Written as CKD-314+SOC
- A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 PneumoniaCompletedPhase 2Chong Kun Dang PharmaceuticalNCT04623021Written as Nafamostat Mesilate
- Clinical Efficacy of Nafamostat Mesylate for COVID-19 PneumoniaStatus unknownPhase 2/3Gyeongsang National University HospitalNCT04418128Written as Nafamostat Mesylate
- Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement TherapyCompletedPhase 4Kyungpook National University HospitalNCT02478242Written as Nafamostat mesilate
Codes
What other systems call nafamostat · ClinicalTrials.gg INT002992
- MeSH (NLM) C032855nafamostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Y25LQ0H97DNAFAMOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q15409374nafamostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96292NafamostatOne source FDA
- DrugBank DB12598One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C032855 | nafamostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Y25LQ0H97D | NAFAMOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15409374 | nafamostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96292 | Nafamostat | One source FDA |
| DrugBank | DB12598 | — | One source Wikidata |
Also registered as nafamostat mesylate (UNII 1D2T74921W).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.